FB1 treatment results in accumulation of Sa1P primarily in the nucleus of MEFs.
FB1 treatment and elevated nuclear Sa1P are associated with HDAC inhibition.
Sphk2 inhibition alone significantly decreases nuclear Sa1P in response to FB1.
Sphk1 and Sphk2 inhibitors prevent nuclear Sa1P accumulation in response to FB1.